We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effects of Antidepressant on Postsynaptic Signal Transduction in Serotonergic System of Depressed Patients

This study is ongoing, but not recruiting participants.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01352572
First Posted: May 12, 2011
Last Update Posted: December 31, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Doh Kwan Kim, Samsung Medical Center
  Purpose
The purpose of this study is to determine whether alteration of signal transduction components after antidepressant targeting, predict antidepressant responsiveness in advance before the appearance of the drug effects until 4~6 weeks after drug administration, or represent the clinical status of depressed patients.

Condition Intervention
Depression Drug: antidepressant response Drug: antidepressant non-response

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Double (Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Effects of Antidepressant on Postsynaptic Signal Transduction in Serotonergic System of Depressed Patients

Resource links provided by NLM:


Further study details as provided by Doh Kwan Kim, Samsung Medical Center:

Primary Outcome Measures:
  • Antidepressant Response at 6 weeks [ Time Frame: 6 weeks ]

    Rsponse is defined as decrease rate of HAM-D score for 6week of treament is = or >50%

    Measurement Unit = responders, nonresponders



Secondary Outcome Measures:
  • Biological value at 0 and 6 weeks [ Time Frame: 6 weeks ]

    Biologial value is defined as protein expression value of signaling components in peripheral lymphocyte.

    Measurement value : Optical Density(O.D), microgram/liter(ug/l)



Estimated Enrollment: 300
Study Start Date: January 2002
Estimated Study Completion Date: December 2018
Estimated Primary Completion Date: December 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: antidepressant response
antidepressant response are refered the patients having a 50 ≤ Decrease rate(%) of HAM-D score
Drug: antidepressant response
Antidepressants administration for 6 weeks under therapeutic dose responders
Other Names:
  • fluoxetine_Prozac
  • paroxetine_Paxil, Seroxat
  • sertraline_Zoloft
  • milnacipran
  • venlafaxine_Effexor
  • nortriptyline_Aventyl, Pamelor, Noritren
  • mirtazapine_Avanza, Zispin, Remeron
Active Comparator: antidepressant non-response
antidepressant non-response are refered the patients having a 50 > Decrease rate(%) of HAM-D score
Drug: antidepressant non-response
Antidepressants administration for 6 weeks under therapeutic dose nonresponders
Other Names:
  • fluoxetine, paroxetine, sertraline
  • milnacipran, venlafaxine, nortriptyline, mirtazapine

Detailed Description:
The purpose of this study is to determine whether antidepressants effect on signal transduction in peripheral lymphocyte and to determine whether the signaling differences between drug responders and nonresponders predict the antidepressant response or represent the clinical status of depressed patients.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. met the Diagnostic and Statistical Manual of the American Psychiatric Association (DSM-IV) criteria for MDD from the Department of Psychiatry, Sungkyunkwan University, Seoul, South Korea.
  2. were 18 years of age or older, the existence of a unipolar major depressive episode as verified by DSM-III/IV criteria, at least 2 years after first episode onset, and agreement to informed consents

Exclusion Criteria:

  • pregnancy
  • significant medical conditions
  • abnormal laboratory baseline values
  • unstable psychiatric features (e.g, suicidal attempt)
  • history of alcohol or drug dependence, seizure, neurological illness, or concomitant Axis I psychiatric disorder
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01352572


Locations
Korea, Republic of
Samsung Medical Center
Kangnam, Seoul, Korea, Republic of, 135-710
Sponsors and Collaborators
Samsung Medical Center
Investigators
Principal Investigator: Doh Kwan Kim, MD PhD Samsung Medical Center
  More Information

Responsible Party: Doh Kwan Kim, M.D., pHD, Samsung Medical Center
ClinicalTrials.gov Identifier: NCT01352572     History of Changes
Other Study ID Numbers: 2002-09-08
First Submitted: April 21, 2011
First Posted: May 12, 2011
Last Update Posted: December 31, 2015
Last Verified: December 2015

Keywords provided by Doh Kwan Kim, Samsung Medical Center:
Antidepressant Response
Signal Transduction
Lymphocyte
Biomarkers
Depressed Patients
Antidepressant Drug Adverse Reaction

Additional relevant MeSH terms:
Depression
Behavioral Symptoms
Antidepressive Agents
Sertraline
Paroxetine
Fluoxetine
Venlafaxine Hydrochloride
Mirtazapine
Milnacipran
Nortriptyline
Psychotropic Drugs
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Serotonin Agents
Physiological Effects of Drugs
Antidepressive Agents, Second-Generation
Cytochrome P-450 CYP2D6 Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Enzyme Inhibitors
Serotonin and Noradrenaline Reuptake Inhibitors
Adrenergic alpha-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Antidepressive Agents, Tricyclic
Histamine H1 Antagonists
Histamine Antagonists
Histamine Agents